23andMe Holding Co
ME
Company Profile
Business description
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Contact
349 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 938-6300
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2025
Employees
582
Stocks News & Analysis
stocks
The lessons behind the best performing stock over the last 80 years
4 factors that led to the incredible returns of Philip Morris.
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,055.30 | 34.60 | -0.43% |
| CAC 40 | 8,159.96 | 45.39 | 0.56% |
| DAX 40 | 23,239.73 | 140.97 | -0.60% |
| Dow JONES (US) | 41,822.27 | 240.96 | 0.58% |
| FTSE 100 | 8,707.86 | 2.63 | 0.03% |
| HKSE | 24,771.14 | 30.57 | 0.12% |
| NASDAQ | 17,631.59 | 127.48 | 0.73% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,045.93 | 30.92 | -0.26% |
| S&P 500 | 5,645.75 | 31.09 | 0.55% |
| S&P/ASX 200 | 7,828.30 | 32.10 | -0.41% |
| SSE Composite Index | 3,426.43 | 3.33 | -0.10% |